





an Open Access Journal by MDPI

Combination Therapy in Gastrointestinal Cancers

Guest Editor:

Dr. Hiroyuki Uetake

Department of Clinical Research, National Hospital Organization Disaster Medical Center, Tokyo, Japan

Deadline for manuscript submissions:

closed (31 October 2023)

Message from the Guest Editor

Cancers of the gastrointestinal tract (GICs) remain at the top of the list of leading causes of death worldwide. This Special Issue on "Combination Therapy for GI Cancers" will show a different perspective on improving the activity of GI cancer treatment by designing combination therapies and developing strategies for combining them with other treatment options. Although many questions may remain unanswered, we hope that this Special Issue will contribute to an awareness and understanding of the power of well-designed combination therapies. Special attention will be given to translating these findings into the clinic.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

- 1. Chemotherapy for gastrointestinal cancers;
- 2. New immunological (chemotherapeutic) combinations for gastrointestinal cancers;
- 3. Potential partners for radiotherapy;
- 4. New combinatorial approaches for locally advanced tumors.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Shahid Ahmed

Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada 2. Saskatchewan Cancer Agency,

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as incoming Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Author Benefits

Open Access: free for readers, with <u>article processing charges (APC)</u> paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (Oncology)

Contact Us